February 24-25, 2027 | Boston, MA

www.viral-vector-process-development.com

COMPLIMENTARY* PASSES FOR BIOTECH & PHARMA

5th Annual

Viral Vector Process Development & Manufacturing Summit

Building a Robust, Reliable & Reproducible Viral Vector Platform

Accelerating Low-Cost Production of Consistent, Safe & Scalable Vectors for Cell & Gene Therapy to Ensure Regulatory Compliance & Clinical Success

Expert Speakers Include:



Jorge Santiago-Ortiz
Vice President, Chemistry, Manufacturing & Controls & Regulatory Affairs
Apertura Gene Therapy



Aditya Dandekar
Director, Technical Development
Cabaletta Bio



Julia Rohlhill
Associate Director, Viral Vector Sciences
Legend Biotech



Andrew Tustian
Executive Director, Preclinical Manufacturing & Process Development
Regeneron



Ying Liu
Associate Director, Cell Culture & Process Development, Genomic Medicine Unit
Sanofi



Mukesh Mayani
Senior Director, Global CMC Development
Ultragenyx

Proud to Partner With:

Lonza | Boston BioProducts

+1 617 455 4188 info@hansonwade.com
www.viral-vector-process-development.com Cell & Gene Therapy Event Series
hansonwade

Optimize Viral Vector Manufacturing to Deliver Safer, Scalable & Cost-Efficient Cell & Gene Therapies

5th Annual Viral Vector Process Development & Manufacturing Summit

February 24-25, 2027 | Boston, MA

+70% of Case Studies Feature New Data

The viral vector industry is entering a new phase of maturity. As the focus shifts from platform innovation to accelerating clinical development, scalable and reproducible CMC strategies are becoming essential for reducing risk, strengthening regulatory confidence, and supporting long-term commercial success.

Returning for its **5th year**, the **Viral Vector Process Development & Manufacturing Summit** unites 100+ leaders across **CMC**, **process development**, **manufacturing**, **MSAT**, **operations**, and **regulatory affairs** to share practical strategies for building scalable and cost-effective viral vector platforms.

Discover how to build **robust**, **reliable**, and **reproducible** manufacturing systems that accelerate programs into the clinic and through to commercialization, while ensuring sustainable, scalable, and consistent manufacturability at every stage of development and commercial production.

Join Industry Peers to:

- **Optimize established AAV and LVV platforms** to accelerate clinical progression with greater confidence
- **Implement robust, reproducible CMC systems** to improve product quality, manufacturing consistency, and regulatory readiness
- **Advance scalable manufacturing processes** to increase yields, reduce cost of goods (COGs), and support commercialization efforts
- **Apply platform-based development strategies** to shorten timelines, reduce development risk, and maximize prior investments

Join experts from **Ultragenyx**, **Regeneron**, **Sanofi**, **Cabaletta Bio**, **Legend Biotech**, **Apertura Gene Therapy**, and more to advance vector quality, accelerate scalable manufacturing, and build the regulatory confidence needed for clinical and commercial success.

What Our Speakers Have to Say

"What excites me most about attending is the chance to learn directly from industry peers and hear practical, real-world perspectives. I'm particularly looking forward to gaining insight into emerging technologies, regulatory trends, and the key challenges influencing the future of gene and cell therapy development."

Senior Director, Global CMC Development, **Ultragenyx**

"This conference provides an excellent opportunity to discuss the challenges and development of AAV with leading experts"

Associate Director, Cell Culture & Process Development, Genomic Medicine Unit, **Sanofi**

Key Benefits of Attending



Accelerate Development Timelines with Proven Platform Manufacturing Strategies
Hear how **Affinia Therapeutics**, **Ultragenyx**, and **Celosia Therapeutics** are leveraging platform manufacturing and FDA Platform Technology Designation to reduce development burden, standardize CMC, and speed clinical progress



Increase Vector Yield While Significantly Reducing Manufacturing Costs
Learn how **Astellas Pharma**, **Sanofi**, and the **National Research Council** are optimizing transfection and producer cell lines to improve yields, reduce variability, and lower manufacturing costs.



Improve Product Quality Through More Efficient Capsid Separation
Explore how advanced purification strategies can increase potent product recovery, enhance purity, and maximize batch value through real-world case studies from **Regeneron** and **Ultragenyx**.



Achieve Commercial Readiness with Scalable Manufacturing Platforms
Understand how platform-ready manufacturing processes can simplify tech transfer, support scale-up, and reduce commercialization risk through practical lessons from **Apertura Gene Therapy** and **Neurocrine Biosciences**.



Lower Therapy Costs Through Smarter CMC Optimization Strategies
Examine approaches for reducing validation burden, increasing manufacturing productivity, and improving affordability to support sustainable commercialization with perspectives from **GenSight Biologics** and **Regeneron**.

+1 617 455 4188 info@hansonwade.com
www.viral-vector-process-development.com Cell & Gene Therapy Event Series
hansonwade

2027 Expert Speakers

Leading Biotech Experts



Aditya Dandekar
Director, Technical Development
Cabaletta Bio



Jing Li
Associate Director, Analytical Tech Transfer & CMC Team Lead
Alexion Pharmaceuticals



Jorge Santiago-Ortiz
Vice President, Chemistry, Manufacturing & Controls & Regulatory Affairs
Apertura Gene Therapy



Julia Rohlhill
Associate Director, Viral Vector Sciences
Legend Biotech



Jack Ren
Director, Downstream Process Development, Global CMC Development
Ultragenyx

Jessie Sun
Senior Director, MSAT
Ultragenyx



Matthew Edwards
Vice President, Technical Operations
Affinia Therapeutics



Michael White
CMC Lead
Celosia Therapeutics



Mukesh Mayani
Senior Director, Global CMC Development
Ultragenyx



Pranav Puri
Head of BioProcess Development
VectorY Therapeutics



Seth Levy
Vice President, Manufacturing
Modalis Therapeutics



Scott Jeffers
Chief Technology Officer
GenSight Biologics



Wenbin Qi
Associate Director
Neurocrine Biosciences

Pharma Industry Leaders



Andrew Tustian
Executive Director, Preclinical Manufacturing & Process Development
Regeneron



Brooke Hodge
Scientist I
Astellas Pharma



Ying Liu
Associate Director, Cell Culture & Process Development, Genomic Medicine Unit
Sanofi



Zhe Zhang
Associate Director
Regeneron

Pioneering Research Institutes



Aziza Manceur
Research Officer, National Research Council
Biotechnology Research Institute

Conference Day One
Wednesday, February 24



Matthew Edwards
Vice President
Technical Operations
Affinia Therapeutics

8.55 **Chair's Opening Remarks**

Building Platform-Ready Viral Vector Manufacturing Processes to Increase Vector Productivity & Regulatory Confidence



Jorge Santiago-Ortiz
Vice President, CMC & Regulatory Affairs
Apertura Gene Therapy
NEW DATA

9.00 **Scalable Novel Engineered Capsids: From Platform Manufacturability to First-in-Human**

- Demonstrating that a novel engineered capsid can be manufactured on existing platform processes with productivities and yields comparable to AAV9 and confirmed at 500L clinical scale
- Building the capsid access and tech transfer infrastructure that lets partners move quickly: established master cell banks and rep-cap plasmid at CDMOs, plus low-friction material transfer pathways for academic, foundation, and industry programs
- Constructing an FDA-informed, MOA-driven CMC and preclinical package for a human receptor-targeted capsid to support regulatory filings and first-in-human dosing



Wenbin Qi
Associate Director
Neurocrine Biosciences
NEW DATA

9.30 **Harnessing Integrated DOE Strategies Across Upstream & Downstream Development to Maximize AAV Productivity**

- Implementing carefully designed DOE studies during transfection development to increase AAV productivity while maintaining process robustness
- Incorporating full-to-empty capsid ratio considerations during upstream optimization to simplify downstream purification and improve product quality
- Connecting upstream process decisions with downstream empty/full separation strategies to increase development success and overall manufacturing efficiency

10.00 **Fireside Chat: Leveraging FDA Platform Technology Designation Program Learnings to Accelerate Multi-Program Development & Reduce Redundant Studies**

- Understanding regulatory interactions and data package requirements for platform designation applications, positioning companies to benefit from streamlined review processes and reduced filing burdens
- Sharing knowledge from companies that have successfully obtained platform designation to reduce redundant development, saving years of process characterization work and millions in development costs
- Navigating applicability of platform approaches for small companies with single assets versus large multi-program portfolios, determining when platform investment delivers meaningful return

Moderated by



Mukesh Mayani
Senior Director, Global CMC Development
Ultragenyx



Matt Edwards
Vice President
Technical Operations
Affinia Therapeutics



Michael White
CMC Lead
Celosia Therapeutics



10.45 **Speed Networking**
Building robust, scalable, and cost-effective viral vector manufacturing processes cannot be solved in silos. This structured networking session gives you the opportunity to connect with peers, exchange ideas, benchmark strategies, and build relationships with the leaders advancing viral vector manufacturing



11.15 **Morning Refreshment Break**

Leveraging Viral Vector Platform Processes to Accelerate Development & Reduce CMC Burden



Aditya Dandekar
Director, Technical Development
Cabaletta Bio
NEW DATA

11.45 **Partnering With Established Viral Vector Manufacturing Platforms to Accelerate PPQ Readiness & Reduce Commercialization Risk**

- Partnering with experienced viral vector CDMOs to accelerate commercialization readiness through proven manufacturing expertise and regulatory support
- Leveraging established platform knowledge to streamline process characterization activities and reduce validation timelines, costs, and resource burden
- Utilizing manufacturing experience and historical data to strengthen regulatory responses and demonstrate consistent PPQ performance

Conference Day One
Wednesday, February 24

12.15 **Session Details to be Announced**

12.45 **Lunch Break & Networking**

Developing Robust Vector Purification Platforms to Improve Yield, Purity & Scalability



Mukesh Mayani
Senior Director, Global CMC Development
Ultragenyx
NEW DATA

1.45 **Advancing Empty/Full Capsid Separation Technologies to Increase Potent Product Yield & Minimize Manufacturing Costs**

- Evaluating novel chromatography resins and purification modalities to improve separation of genome-containing versus non-genome-containing capsids, reducing the significant product losses that drive up cost per dose
- Implementing emerging analytical technologies including mass photometry, nanomosaic and analytical ultracentrifugation (AUC) for enhanced empty/full characterization to support regulatory filing confidence and process optimization
- Optimizing purification strategies to achieve higher purity levels while maintaining acceptable recovery rates and infectious titer, delivering more doses per batch for improved patient access

2.15 **Session Details to be Announced**

2.25 **Poster Session & Afternoon Break**
Explore the latest viral vector manufacturing innovations and practical case studies in this interactive poster session, showcasing approaches to improve productivity, strengthen process robustness, optimize purification, and accelerate scalable AAV, LVV and more novel viral vector production.

Reducing Viral Vector Development & Manufacturing Costs to Enable Sustainable Clinical Commercialization



Scott Jeffers
Chief Technology Officer
GenSight Biologics

3.30 **Minimizing Chemistry, Manufacturing & Controls (CMC) Burden for Rare & Ultra-Rare Disease Programs to Enable Small Company Success**

- Streamlining validation package requirements and Process Performance Qualification (PPQ) batch strategies to reduce multi-million-dollar costs that threaten program viability for single-asset developers
- Balancing regulatory compliance with practical cost constraints for small companies, implementing efficient approaches that meet agency standards without excessive financial burden
- Implementing efficient process development strategies that achieve regulatory approval while preserving capital for clinical trials and commercial launch preparation



Zhe Zhang
Associate Director
Regeneron
NEW DATA

4.00 **Increasing Productivity as the Root Cause Solution to Cost Challenges & Long-Term Market Viability**

- Improving upstream yields and downstream recoveries to generate more doses per batch and dramatically reduce cost per dose, making therapies accessible to broader patient populations
- Comparing cost of goods across industry to establish benchmarks and identify improvement opportunities, leveraging best practices to accelerate cost reduction initiatives
- Ensuring business sustainability by bringing manufacturing costs down to accessible price points, enabling reimbursement approval and global market expansion

4.30 **End of Conference Day One**

Conference Day Two
Thursday, February 25



Julia Rohlhill
Associate Director, Viral Vector Sciences
Legend Biotech

8.55 **Chair's Opening Remarks**

Implementing Stable Producer & Packaging Cell Line Strategies to Reduce Manufacturing Complexity & Improve Process Robustness



Ying Liu
Associate Director, Cell Culture & Process Development, Genomic Medicine Unit
Sanofi
NEW DATA

9.00 **Evolving AAV Manufacturing: Comparing Transient Transfection & Producer Cell Line Platforms to Enable Scalable Gene Therapy Production**

- Managing transient transfection variability at scale to improve manufacturing consistency, reduce operational complexity and support reliable pipeline delivery
- Comparing transient transfection and producer cell line platforms to inform technology selection decisions based on technical, operational and economic requirements
- Optimizing producer cell line clone selection workflows through scale-down screening models to accelerate high-performing clone identification and process development



Brooke Hodge
Engineer I, Upstream Process Development (Gene Therapy)
Astellas Pharma
NEW DATA

9.30 **Improving Triple Transfection Consistency to Reduce Batch-to-Batch Variability & Minimize Manufacturing Risk**

- Addressing transfection cocktail stability challenges and time-sensitive nature of plasmid-reagent complexation, preventing the batch failures that waste resources and delay clinical supply
- Optimizing mixing and pumping parameters to ensure uniform delivery of transfection complexes to cells, achieving consistent yields and quality attributes that support reliable manufacturing
- Implementing quality measurements of transfection cocktails before use to predict and prevent batch failures, reducing the costly losses that occur when transfection variability impacts downstream performance

10.00 **Morning Refreshment Break & Networking**

Scaling Viral Vector Manufacturing Processes to Maintain Product Quality & Ensure Clinical & Commercial Readiness

11.00 **Panel Discussion: Establishing Risk-Based Process Development Decision Frameworks to Accelerate Clinical Progression**

- Defining fit-for-purpose process performance criteria to accelerate clinical progression while maintaining robust, reliable and reproducible viral vector manufacturing
- Assessing technology adoption and supplier diversification strategies to reduce operational risk while maximizing value from established manufacturing platforms
- Balancing process optimization efforts against program timelines, manufacturing costs and patient demand to enable data-driven development decisions

Moderated by



Julia Rohlhill
Associate Director, Viral Vector Sciences
Legend Biotech

Jessie Sun
Senior Director, MSAT
Ultragenyx



Jing Li
Associate Director, Viral Vector Analytical Tech Transfer
Alexion – AstraZeneca Rare Disease



Seth Levy
Vice President, Manufacturing
Modalis Therapeutics

Conference Day Two
Thursday, February 25



Pranav Puri
Associate Director, BioProcess Development
VectorY Therapeutics
NEW DATA

11.45 Showcasing Insect Cell-Based AAV Manufacturing Capabilities to Enable Scalable Clinical & Commercial Production

- Demonstrating an insect cell-based AAV production platform with proven process development strategies to achieve robust clinical manufacturing readiness
- Presenting a 1,000L clinical manufacturing case study with regulatory-approved quality outcomes to validate large-scale production performance
- Leveraging scalable 1,000L AAV manufacturing capabilities for neurodegenerative therapies to support broader patient access efficiently



Jack Ren
Director, Downstream Process Development, Global CMC Development
Ultragenyx
NEW DATA

12.15 Leveraging Platform & Prior Knowledge for Accelerated PPQ Campaign & Commercial Readiness Under Compressed CMC Timelines

- Establishing risk-based process characterization strategies using platform knowledge to accelerate development activities without compromising regulatory expectations
- Implementing streamlined PPQ planning and execution approaches to achieve manufacturing readiness despite limited time, historical data and resources
- Applying platform-derived control strategies to strengthen regulatory submissions, expedite CMC preparedness and support successful product approval

12.45 Lunch Break & Networking

Strengthening Sponsor-CDMO Tech Transfer Alignment to Accelerate Manufacturing Readiness & Clinical Timelines

Moderated by



Julia Rohlhill
Associate Director, Viral Vector Sciences
Legend Biotech

1.45 Roundtable Discussion: Overcoming Tech Transfer Bottlenecks Through Better Sponsor-CDMO Collaboration to Accelerate Manufacturing Readiness

- Identifying documentation gaps, batch record deficiencies and training challenges to improve first-time-right tech transfer execution
- Strengthening sponsor-CDMO communication practices to reduce transfer failures, rework cycles and manufacturing delays
- Benchmarking successful transfer approaches and lessons learned from failures to accelerate clinical timelines and patient access

Optimizing Upstream Production Platforms & Downstream Purification Strategies to Reduce Viral Vector Manufacturing Costs



Aziza Manceur
Research Officer
National Research Council

2.45 Implementing Packaging & Producer Cell Lines to Eliminate Plasmid Transfection Complexity & Reduce Manufacturing Costs

- Evaluating stable producer cell lines as alternatives to transient transfection for simplified GMP manufacturing, eliminating the expensive plasmid costs and transfection variability that drive up manufacturing expenses
- Assessing quality comparisons between transient transfection and stable cell line-derived vectors, ensuring product comparability and regulatory acceptability when transitioning platforms
- Understanding cost-benefit analysis including development timelines, productivity and regulatory considerations, making informed decisions on when producer cell line investment delivers meaningful return

Conference Day Two
Thursday, February 25



Andrew Tustian
Executive Director, Preclinical Manufacturing & Process Development
Regeneron

NEW DATA

3.15 **Optimizing Anion Exchange Chromatography Strategies to Enhance AAV Empty-Full Capsid Separation Efficiency**

- Establishing anion exchange chromatography as a critical purification strategy to maximize empty-full capsid separation across AAV manufacturing processes
- Comparing multiple anion exchange chromatography approaches to select the most effective strategy for specific AAV process requirements
- Aligning anion exchange method selection with serotype characteristics, impurity load and partial capsid distribution to improve purification performance



Julia Rohlhill
Associate Director, Viral Vector Sciences
Legend Biotech

3.45 **Chair's Closing Remarks**

3.50 **End of Conference Day Two**

"The smaller environment compared to BPI provided a better opportunity to get to know people directly in the same field and discuss our shared challenges and opportunities. Really good lineup of speakers and data sharing"

2026 Attendee, Assistant Director, Downstream, **NC State University**

"I loved the atmosphere of the conference and the fact that everyone was so willing to share ideas. I also found the organizers to be kind and very helpful!"

2025 Speaker, Supervisor Lentivirus Manufacturing Excellence Investigations, **Johnson & Johnson**

2027 Partners

Expertise Partner

Lonza is one of the world's largest contract development and manufacturing organizations (CDMOs) dedicated to serving the healthcare industry. Working across five continents, our global team of around 18,500 colleagues works alongside pharma and biotech companies to turn their breakthrough innovations into viable therapies. We support our customers in bringing life-saving and life-enhancing treatments to patients worldwide with a combination of cutting-edge science, smart technology and lean manufacturing.

www.lonza.com

Innovation Partner

We are on a mission to formulate solutions for scientific breakthrough discoveries by reliably delivering fit-for-purpose buffers so that researchers and drug developers can focus on their science. Whether we are producing common or custom buffers, we provide services our customers can trust every time.

Boston BioProducts has 50+ team members, operates under a cGMP quality management system, and provides buffers to 4,000+ labs worldwide.

www.bostonbioproducts.com

"Extremely curated attendees and content for our technology. The smaller group made it more amenable to meeting everyone at some point. Also loved the speed networking!"

Vice President, Sales & Marketing, **Cellevate AB**
2025 Sponsor

Get Involved



Oliver Smare
Partnerships Director
Tel: +1 617 455 4188
Email: sponsor@hansonwade.com

Take the Spotlight & Partner With Us

5th Annual Viral Vector Process Development & Manufacturing Summit

February 24-25, 2027 | Boston, MA

Connect with Biopharma Shaping the Future of Viral Vector Manufacturing

The **5th Viral Vector Process Development & Manufacturing Summit** brings together leading viral vector developers, including **Ultragenyx**, **Regeneron**, **Sanofi**, **Legend Biotech**, **Cabaletta Bio**, **Apertura Gene Therapy**, and other organizations seeking to optimize manufacturing processes to increase the accessibility and affordability of cell and gene therapies without compromising product quality.

As industry shifts towards optimizing proven platforms, companies are increasingly focused on building robust, reliable, and reproducible manufacturing processes that reduce costs, improve scalability, and strengthen regulatory confidence. However, achieving these goals requires more than internal expertise alone.

To make the right process decisions, improve manufacturing performance, and streamline commercialization pathways, organizations are actively seeking support from **CDMOs**, **reagent providers**, **analytical and assay providers**, **delivery technology companies**, **and viral vector manufacturing solution providers**.

Partner with this Meeting to:

Position Your Brand at the Center of Viral Vector Innovation

Showcase how your solutions help improve scalability, consistency, and affordability across viral vector manufacturing. Engage directly with decision-makers seeking reliable partners, building the credibility and visibility needed to **influence future purchasing and partnership decisions**.


Connect with a Highly Targeted Viral Vector Audience

Connect directly with viral vector process development and manufacturing leaders actively seeking new solutions. Target the companies and stakeholders most relevant to your business and **accelerate meaningful commercial conversations**.

Gain Insight into Emerging Manufacturing & CMC Challenges


Hear how leading developers are tackling **transfection**, **cell expansion**, **purification**, **analytical decision-making**, **and process scalability**. Identify unmet needs impacting yield and cost to **better position your solutions and refine your services around evolving customer priorities**.

Seniority of Attendees



- C Level – 8%
- President / VP – 12%
- Director/Head– 38%
- Manager – 23%
- Scientist – 17%
- Other –2%

Type of Companies Attending



- Drug Developers
- Service Providers
- Regulators & Academics
- Others

*Audience Breakdown from the 4th Viral Vector Process Development & Manufacturing Summit

Partner with Us



Oliver Smare
Partnerships Director
Tel: +1 617 455 4188
Email: sponsor@hansonwade.com

Ready to Register?

3 Easy Ways to Book

www.viral-vector-process-development.com/register

Tel: +1 617 455 4188

Email: info@hansonwade.com

OPTIMIZE proven AAV and LVV manufacturing processes to improve vector quality, increase yields, reduce cost of goods, and accelerate clinical progression without compromising product consistency.

DISCOVER practical strategies for building robust, reliable, and reproducible CMC systems that strengthen regulatory confidence, support platform approaches, and enable successful scale-up and commercialization.

ENGAGE with a community of viral vector leaders across process development, manufacturing, MSAT, CMC, operations, and regulatory affairs to benchmark approaches, solve shared challenges, and build valuable industry connections.

Drug Developers & Research Institutes**	
Access to Conference	FREE*

Registration is FREE* if you work for a drug developer, research organization, or academic institution. *Please note that credit card details will be taken upon registration, and a nominal fee of $0.50 charged. This amount is fully refundable at the end of the month in which the event takes place, provided you attend the event. **A drug developer, researcher or academic must have a pipeline candidate and/or work for an academic institution, and must not provide solutions or services for a fee to any other company. Free access is only granted once approval of eligibility is confirmed. Hanson Wade retain the right to reject or cancel your registration if eligibility criteria are not met, and paid registration will then be required to access the event. Hanson Wade reserves the right to charge free access guests a non-refundable charge of $100 if they do not attend the entire event if they fail to give 7 working days' notice of nonattendance.

Service & Solution Providers Pricing***	Register & Pay by Friday, January 22	On the Door Price
Access to Conference	$3,599	$4,099

***Service and Solution Providers refer to all employees from Consultancies, CRO, CDMOs, Raw Material, Equipment, Analytics and Assay Providers who partner with, or provide services to, drug developers and/or research organizations.

Team Discounts****

- **10% discount – 2 Attendees**
- **15% discount – 3 Attendees**
- **20% discount – 4+ Attendees**

****Please note that discounts are only valid when two or more delegates from one company book and pay at the same time.

Discounts cannot be used in conjunction with any other offer or discount. Only one discount offer may be applied to the current pricing rate.

Contact: register@hansonwade.com



Venue

The Colonnade Hotel
120 Huntington Ave, Boston, MA 02116, United States
For further Information or assistance, please visit:
www.colonnadehotel.com

TERMS & CONDITIONS

Full payment is due on registration. Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organization can be made at any time.

Changes to Conference & Agenda: Every reasonable effort will be made to adhere to the event programme as advertised. However, it may be necessary to alter the advertised content, speakers, date, timing, format and/or location of the event. We reserve the right to amend or cancel any event at any time. Hanson Wade Conferences Limited is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities.

Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Hanson Wade Conferences Limited, Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH, United Kingdom